Colin MD Broom - 28 Jul 2021 Form 4 Insider Report for Nabriva Therapeutics plc (NBRVF)

Role: Director
Signature: /s/ Robert Crotty, by power of attorney
Issuer symbol: NBRVF
Transactions as of: 28 Jul 2021
Net transactions value: $0
Form type: 4
Filing time: 30 Jul 2021, 20:22:02 UTC
Next filing: 04 Aug 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NBRVF	Ordinary Shares	Award	$0	+17,500	+70%	$0.000000	42,393	28 Jul 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NBRVF	Share Options	Award	$0	+35,000		$0.000000	35,000	28 Jul 2021	Ordinary Shares	35,000	$1.08	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units.
F2	The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020.
F3	The option was granted on July 28, 2021.
F4	One hundred percent (100%) of the option will vest on July 31, 2022, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc.